XORTX Therapeutics Inc.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to improve the quality of life for patients with gout and progressive kidney disease. Their programs aim to manage aberrant purine metabolism and reduce high uric acid levels to alleviate gout symptoms and slow the progression of related kidney diseases.

Products & Services

XRx-026:A treatment for gout patients, particularly those who do not respond well to the standard care (allopurinol), nearing NDA filing stage.

XRx-008:A therapy for autosomal dominant polycystic kidney disease (ADPKD), addressing declining kidney function and associated cardiovascular issues.

XRx-101:A novel formulation of oxypurinol for acute kidney disease and health issues related to serious viral infections like Coronavirus/COVID-19.

XRx-225:A co-developed treatment for Type 2 Diabetic Nephropathy (T2DN), a common cause of chronic kidney failure and end-stage kidney disease.

Specialties

Gout treatment Progressive kidney disease therapies Uric acid lowering agents Autosomal dominant polycystic kidney disease (ADPKD) Type 2 Diabetic Nephropathy (T2DN) Coronavirus-related kidney disease treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1102500 MR: - FA: US$1.1 Million FAN: 1102500	D: 2025-10-29 FD: 2025-10-29	1 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: US$1.1 Million FAN: 1100000	D: 2025-10-21 FD: 2025-10-21	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 114500 MR: - FA: US$114,500 FAN: 114500	D: 2025-08-08 FD: 2025-08-08	-
4	RT: Private Placement T: - FT: Private Placement	A: 114500 MR: - FA: USD $114,500 FAN: 114500	D: 2025-07-31 FD: 2025-07-31	-
5	RT: Private Placement T: - FT: Private Placement	A: 925000 MR: - FA: US$925,000 FAN: 925000	D: 2025-07-22 FD: 2025-07-22	-
6	RT: Private Placement T: - FT: Private Placement	A: 925000 MR: - FA: USD $925,000 FAN: 925000	D: 2025-06-26 FD: 2025-06-26	-
7	RT: Private Placement T: - FT: Private Placement	A: 3000000 MR: - FA: 3,000,000 FAN: 3000000	D: 2025-05-19 FD: 2025-05-19	-
8	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 1500000 MR: - FA: US$1.5 million FAN: 1500000	D: 2024-10-18 FD: 2024-10-18	1 investors
9	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 1500000 MR: - FA: US$1.5 million FAN: 1500000	D: 2024-10-17 FD: 2024-10-17	1 investors
10	RT: Warrant Repricing T: - FT: Warrant Repricing	A: 5120495 MR: - FA: 5,120,495 FAN: 5120495	D: 2024-04-30 FD: 2024-04-30	-
11	RT: ATM Offering T: - FT: ATM Offering	A: 3701931 MR: - FA: US$3,701,931 FAN: 3701931	D: 2023-11-30 FD: 2023-11-30	1 investors

Registered Direct Offering Latest

2025-10-29

$1.1M

1 investor (Pro only)

Registered Direct Offering 2025-10-21

$1.1M

Private Placement 2025-08-08

$114K

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dr. Richard J Johnson Jr., MD

Professor of Pediatrics and Associate Dean for Research and Development, University of Colorado School of Medicine

D

Dr. Henk E. D. J. ter Keurs, MD, PhD

Cardiologist

D

Dr. Petter Bjornstad, MD

Clinical Researcher and Assistant Professor of Pediatrics and Medicine, University of Colorado School of Medicine

D

Dr. Fred Maese, MD

Cardiologist and Clinical Researcher

D

Dr. Anjay Rastogi, MD PhD

Professor and Clinical Chief of Nephrology

D

Dr. Charles Edelstein, MD PhD

Professor of Medicine and Nephrologist

View 15 more team members with Pro

Unlock Full Team Directory

Recent News